Welcome to our dedicated page for LeonaBio SEC filings (Ticker: LONA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
LeonaBio, Inc. SEC filings document the company’s status as a Delaware clinical-stage biopharmaceutical issuer listed on The Nasdaq Capital Market under the LONA ticker. Its 8-K reports furnish financial results, business updates, Regulation FD disclosures, board matters, and material events tied to its product candidates and corporate development activity.
Registration statement amendments cover delayed or continuous securities offerings, while amended material-event filings document the completed Sermonix license transaction, related securities issuance, and SEC accounting disclosures under Regulation S-X. The filing record also reflects the company’s transition from Athira Pharma to LeonaBio and the capital-structure disclosures associated with its common stock and warrants.
LeonaBio, Inc. director Fred Callori received a grant of stock options covering 2,333 shares of common stock at an exercise price of $8.35 per share. These options vest on the earlier of June 23, 2027 or just before the next annual stockholder meeting after June 22, 2026 and expire on June 22, 2036.
LeonaBio, Inc. director Natalie C. Holles received a grant of stock options covering 2,333 shares of common stock. The options have an exercise price of $8.35 per share and are held as a direct ownership position.
According to the grant terms, these options vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026. The grant was issued under LeonaBio’s Outside Director Compensation Policy and was pro-rated based on her appointment to the board on May 5, 2026. After this grant, her reported option holdings from this award total 2,333 shares and expire on June 22, 2036.
LeonaBio, Inc. director Peter B. Silverman received a grant of stock options covering 2,333 shares of common stock. The options have an exercise price of $8.35 per share and expire on June 22, 2036.
The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting held after June 22, 2026. The award was granted under LeonaBio’s Outside Director Compensation Policy and pro-rated based on his board appointment on May 5, 2026.
LeonaBio, Inc. director Michael A. Panzara received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $8.35 per share and expire on June 22, 2036.
The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026. This is a compensation-related award rather than an open-market transaction.
LeonaBio, Inc. director Romano Kelly reported receiving a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $8.35 per share and expire on June 22, 2036.
The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholders’ meeting that occurs after June 22, 2026. The grant was made under LeonaBio’s Outside Director Compensation Policy and reflects equity-based compensation rather than an open-market purchase or sale.
LeonaBio, Inc. director Joseph Edelman received a grant of stock options covering 28,000 shares of common stock at an exercise price of $8.35 per share. The options expire on June 22, 2036 and vest on the earlier of June 23, 2027 or the day before the next annual stockholder meeting after June 22, 2026, under the company’s Outside Director Compensation Policy.
LeonaBio, Inc. director James A. Johnson received a grant of stock options as part of his outside director compensation. He was awarded 28,000 stock options to acquire LeonaBio common stock at an exercise price of $8.35 per share. The options vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026, and expire on June 22, 2036. Following this grant, Johnson holds 28,000 options to purchase LeonaBio common stock directly.
LeonaBio, Inc. director Barbara Kosacz received a grant of stock options as part of outside director compensation. The award covers 28,000 stock options for common stock with an exercise price of $8.35 per share, expiring on June 22, 2036.
The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026. Following this grant, she holds 28,000 derivative securities directly.
LeonaBio director Grant Pickering received a grant of stock options for 28,000 shares of common stock. The options have an exercise price of $8.35 per share and expire on June 22, 2036. All 28,000 options were outstanding after the transaction, held as a direct position.
The options will vest on the earlier of June 23, 2027 or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026. The grant was made under LeonaBio’s Outside Director Compensation Policy, indicating it is part of routine director compensation rather than an open-market purchase.
LeonaBio, Inc. reported the results of its 2026 Annual Meeting of Stockholders. Of 9,393,514 common shares outstanding as of May 1, 2026, 7,908,604 shares were present or represented by proxy, representing approximately 84.19% of shares entitled to vote, which was enough to conduct business.
Stockholders elected three Class III directors—Kelly A. Romano, James A. Johnson and Natalie Holles—to terms running until the 2029 annual meeting, with strong majorities of votes cast in favor. They also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
In advisory votes, stockholders approved the compensation of LeonaBio’s named executive officers and indicated a preference to hold future advisory votes on executive pay every three years. The company and its board plan to follow a three-year frequency until the next required vote on this question.